Citigroup Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Key Points

• Citigroup raised its price target on Neurocrine to $246 and kept a "buy" rating, implying roughly a 69% upside from the current share price.
• In Q1 the company reported revenue of about $805.5M (up ~28.3% YoY) despite an EPS miss; management reaffirmed 2026 Ingrezza net sales guidance of $2.7–$2.8B and announced the acquisition of Soleno Therapeutics to expand the pipeline.
• Multiple analysts have lifted targets (e.g., Piper Sandler to $207, HC Wainwright to $215), the MarketBeat consensus is a "Moderate Buy" with a $183 price target, and institutional ownership is high at roughly 92.6%.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) had its price target hoisted by equities researchers at Citigroup from $242.00 to $246.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock. Citigroup's target price would suggest a potential upside of 69.02% from the company's current price.

A number of other research firms have also recently issued reports on NBIX. Canaccord Genuity Group boosted their target price on Neurocrine Biosciences from $164.00 to $200.00 and gave the company a "buy" rating in a research note on Tuesday, April 7th. Truist Financial cut their price objective on Neurocrine Biosciences from $169.00 to $140.00 and set a "buy" rating on the stock in a report on Tuesday, February 17th. Wedbush increased their target price on Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an "outperform" rating in a research note on Wednesday. Zacks Research upgraded shares of Neurocrine Biosciences from a "strong sell" rating to a "hold" rating in a report on Wednesday, April 15th. Finally, HC Wainwright lifted their price target on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the company a "buy" rating in a research note on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $183.00.

Neurocrine Biosciences Price Performance

NBIX traded up $10.48 during mid-day trading on Wednesday, hitting $145.54. The stock had a trading volume of 1,384,709 shares, compared to its average volume of 1,151,320. The stock's fifty day simple moving average is $130.37 and its 200-day simple moving average is $137.72. The firm has a market capitalization of $14.64 billion, a price-to-earnings ratio of 31.23, a price-to-earnings-growth ratio of 0.67 and a beta of 0.34. Neurocrine Biosciences has a 1-year low of $115.66 and a 1-year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The firm had revenue of $805.50 million during the quarter, compared to analyst estimates of $804.21 million. During the same period last year, the firm earned $1.69 EPS. Neurocrine Biosciences's quarterly revenue was up 28.3% on a year-over-year basis. As a group, research analysts expect that Neurocrine Biosciences will post 6.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of NBIX. JPMorgan Chase & Co. grew its stake in shares of Neurocrine Biosciences by 11.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company's stock worth $664,019,000 after acquiring an additional 468,405 shares in the last quarter. AQR Capital Management LLC increased its stake in Neurocrine Biosciences by 18.0% in the 4th quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company's stock valued at $462,652,000 after buying an additional 498,058 shares during the last quarter. Geode Capital Management LLC lifted its position in Neurocrine Biosciences by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company's stock worth $291,342,000 after buying an additional 34,457 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Neurocrine Biosciences by 7.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company's stock worth $178,248,000 after buying an additional 88,522 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Neurocrine Biosciences by 31.9% during the 4th quarter. Northern Trust Corp now owns 1,221,184 shares of the company's stock worth $173,201,000 after buying an additional 295,470 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

More Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Q1 results beat expectations: revenue of $811.0M (up ~44% YoY), EPS ahead of estimates, INGREZZA sales described as a key driver, and management reaffirmed 2026 INGREZZA net sales guidance of $2.7–$2.8B — a core reason investors are buying the stock. Neurocrine Q1 2026 Financial Results
• Positive Sentiment: Acquisition announced: Neurocrine agreed to acquire Soleno Therapeutics (includes VYKAT XR for hyperphagia in Prader‑Willi), expanding commercial footprint and pipeline — adds potential new revenue stream and diversification. Acquisition Announcement
• Positive Sentiment: Multiple bullish analyst moves: Piper Sandler raised its PT to $207 (overweight), RBC raised its PT to $180 (outperform), Wedbush to $176 (outperform), and Guggenheim reaffirmed a $175 buy — collectively pushing consensus upside and supporting today’s rally. Analyst Price Target Raises
• Positive Sentiment: Peer‑reviewed guidance for CRENESSITY adoption published: expert recommendations in The Journal of Clinical Endocrinology & Metabolism give clinicians practical algorithms to reduce glucocorticoid dosing after starting CRENESSITY, which should help real‑world uptake and positioning in CAH. CRENESSITY Publication
• Neutral Sentiment: Investor outreach: management will present at the Bank of America Health Care Conference (May 12), offering more visibility on execution and the 2027 outlook — a near‑term event investors will watch. BofA Conference Notice
• Neutral Sentiment: Earnings materials/transcript available: slide deck and call transcripts provide detail on drivers (INGREZZA, CRENESSITY launch, pipeline moves) for investors who want to dig into unit economics and margin trajectory. Q1 Slide Deck
• Negative Sentiment: Some market commentary questions valuation/positioning after recent gains — a Yahoo piece asks whether the stock is pricing in too much caution, signaling there are analysts/commentators worried about upside already being in the price. Yahoo Valuation Piece

Neurocrine Biosciences Company Profile

Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.

The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.